{"url_path":"/sec/entx/8-k/2026-07-16/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1638097/0001178913-26-003510-index.html","accession_number":"0001178913-26-003510","cik":"0001638097","ticker":"ENTX","issuer_name":"Entera Bio Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1638097/0001178913-26-003510-index.html","primary_entity_key":"0001638097","primary_entity_name":"Entera Bio Ltd."},"word_count":194,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;\nCompensatory Arrangements of Certain Officers.\n\nAt the Annual Meeting (as defined in Item 5.07 to\nthis Current Report on Form 8-K) of Entera Bio Ltd., a company formed under the laws of the State of Israel (the “Company”), the Company’s shareholders approved an amendment (the “Amendment”) to the Company’s 2018 Equity\nIncentive Plan (the “2018 Equity Incentive Plan”) to increase the number of ordinary shares, par value of NIS 0.0000769, of the Company (“Ordinary\n\nShares”) issuable thereunder by a one-time amount of 2,500,000 Ordinary Shares. The material terms of the 2018 Equity Incentive Plan have been\npreviously reported by the Company and may be found under Proposal 7, contained in the Company’s Definitive Proxy statement on Schedule 14A (the “Proxy Statement”) previously filed with the Securities and Exchange Commission (the “Commission”)\n\non June 3, 2026.\n\nThe foregoing description of the Amendment is only a summary and is qualified in its entirety by the full text of the Amendment,\nwhich is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02."}